系统性硬化症自体造血干细胞移植后治疗相关死亡及主要不良事件的预测因素:长期随访多中心研究结果
该多中心长期随访研究纳入荷兰截至2017年接受自体造血干细胞移植治疗的系统性硬化症患者92例,中位随访4.6年,5年、10年、15年无事件生存率分别为78%、76%和66%。男性、左心室射血分数低于50%及年龄较大是事件的独立相关因素,治疗相关死亡率随时间下降且男性更常见。
要点
- 自体HSCT可显著改善SSc患者皮肤和肺功能,长期无事件生存率较高。
- 男性、基线LVEF低于50%和年龄较大是移植后事件的独立危险因素。
- 治疗相关死亡率随时间下降,但在男性中更常见。
核心结论
- 自体HSCT对系统性硬化症具有长期疗效,可改善生存、皮肤和肺受累。
- 男性、基线左心室射血分数低于50%及年龄较大是移植后事件的独立危险因素。
研究设计与样本
- 荷兰多中心长期随访研究,纳入截至2017年接受自体HSCT治疗的SSc患者92例。
- 收集基线、1年、2年和5年的皮肤、肺功能、高分辨率CT间质性肺病范围及左心室射血分数数据,随访事件至2019年。
- 与环磷酰胺治疗患者及参与ASTIS试验的HSCT患者进行比较。
主要发现
- 中位随访4.6年,5年、10年和15年无事件生存率分别为78%、76%和66%。
- 共发生20例死亡,22例患者出现疾病进展。
- 平均FVC、DLCO、mRSS和Goh评分均显著改善。
- 治疗相关死亡率随时间下降,且在男性中更常见。
- 在ASTIS试验中,HSCT组(n=23)发生7例事件,环磷酰胺组(n=22)发生13例事件。
关键数值与推荐
- 事件定义为死亡或主要器官衰竭。
临床怎么用
- 对于SSc患者,自体HSCT可考虑用于改善长期生存及皮肤、肺受累。
- 移植前应评估男性、左心室射血分数低于50%及年龄较大等危险因素以权衡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autologous haematopoietic stem cell transplantation (HSCT) improves survival in systemic sclerosis (SSc) with poor prognosis, but is hampered by treatment-related mortality (TRM). OBJECTIVE: To evaluate event-free survival (EFS), TRM, response to treatment, disease progression and patient characteristics associated with events. METHODS: All patients treated with HSCT for SSc in The Netherlands until 2017 (n=92) were included. Data on skin involvement (modified Rodnan skin score (mRSS), pulmonary function (forced vital capacity (FVC) and diffusion capacity of the lungs for carbon monoxide (DLCO)), extent of interstitial lung disease on high-resolution CT using Goh scores and left ventricular ejection fraction (LVEF) were collected at baseline, 1, 2 and 5 years. Occurrence of events, defined as death or major organ failure, were collected until 2019. As control, a comparison between patients treated with cyclophosphamide (CYC) and patients with HSCT who participated in the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial was performed. RESULTS: Median follow-up was 4.6 years. EFS estimates at 5, 10 and 15 years were 78%, 76% and 66%, respectively. Twenty deaths occurred. Mean FVC, DLCO, mRSS and Goh scores all improved significantly. Disease progression occurred in 22 patients. Frequency of TRM decreased over time and occurred more often in males. Events were independently associated with male sex, LVEF <50% and older age. In ASTIS, patients treated with HSCT (n=23) 7 events occurred versus 13 in the CYC group (n=22). CONCLUSION: Our data confirm long-term efficacy of HSCT in improving survival, skin and lung involvement in SSc. Male sex, lower LVEF and older age at baseline were identified as risk factors for events.
引用
- van Bijnen S, de Vries-Bouwstra J, van den Ende CH, et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Ann Rheum Dis. 2020. PMID: 32409324. doi:10.1136/annrheumdis-2020-217058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。